Adherex Technologies (FENC) Stock Price, News & Analysis

Company Overview

Adherex Technologies, Inc. is a biotechnology company specializing in the development and commercialization of proprietary life-science research tools and targeted therapeutic platforms. Headquartered in Winston-Salem, North Carolina, the company leverages its in-house expertise in molecular biology, immunology and chemical engineering to create innovative products for pharmaceutical, academic and industrial research laboratories.

The company’s core offerings include its CycloSAM™ targeted delivery platform and complementary diagnostic assay kits designed to advance precision medicine research. CycloSAM enables researchers to selectively deliver molecular payloads to specific cell types, improving cellular uptake and assay sensitivity. In addition, Adherex offers a suite of bioconjugation reagents, assay development services and custom synthesis capabilities to support drug discovery, biomarker identification and translational research initiatives.

Founded in the late 1990s as a spin-out from academic research, Adherex has steadily expanded its product portfolio through in-house innovation and strategic collaborations. Over the years, the company has entered licensing partnerships with leading pharmaceutical firms and spun off technology platforms into joint ventures to accelerate commercialization. Adherex’s leadership team, composed of seasoned biopharma executives and R&D experts, has guided the company through multiple rounds of funding and product launches, positioning it as a recognized supplier to both established and emerging life-science organizations.

While Adherex’s primary operations are based in the United States, the company maintains distribution agreements and research collaborations across Europe and Asia. By combining cutting-edge delivery technologies with tailored assay solutions, Adherex supports a global customer base working on immuno-oncology, cell therapy, infectious diseases and precision diagnostics. The firm continues to invest in pipeline expansion and process improvements to address evolving needs in the life-science research community.

Key Stats

• Today's Range: $8.77 to $9.30
• 50-Day Range: $5.97 to $9.04
• 52-Week Range: $3.96 to $9.30
• Volume: 77,316 shs
• Average Volume: 81,858 shs
• Market Capitalization: $244.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Buy

Adherex Technologies Stock Analysis - MarketRank™

Adherex Technologies scored higher than 46% of companies evaluated by MarketBeat, and ranked 594th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Adherex Technologies has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Adherex Technologies has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Adherex Technologies are expected to decrease in the coming year, from ($0.11) to ($0.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Adherex Technologies is -17.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Adherex Technologies is -17.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.91% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Adherex Technologies has recently decreased by 4.23%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Adherex Technologies does not currently pay a dividend.

Dividend Growth

Adherex Technologies does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.91% of the float of Adherex Technologies has been sold short.

Short Interest Ratio / Days to Cover

Adherex Technologies has a short interest ratio ("days to cover") of 16.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Adherex Technologies has recently decreased by 4.23%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.18

News Sentiment

Adherex Technologies has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Adherex Technologies this week, compared to 2 articles on an average week.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Adherex Technologies insiders have sold 126.33% more of their company's stock than they have bought. Specifically, they have bought $104,602.00 in company stock and sold $236,746.00 in company stock.

Percentage Held by Insiders

11.76% of the stock of Adherex Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.51% of the stock of Adherex Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

FENC Stock Analysis - Frequently Asked Questions

How have FENC shares performed this year?

Adherex Technologies' stock was trading at $6.32 on January 1st, 2025. Since then, FENC shares have increased by 40.3% and is now trading at $8.87.

How were Adherex Technologies' earnings last quarter?

Adherex Technologies Inc. (NASDAQ:FENC) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.08. The firm had revenue of $8.51 million for the quarter, compared to analysts' expectations of $8.18 million.
Read the conference call transcript.

How do I buy shares of Adherex Technologies?

Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Adherex Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Adherex Technologies investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:FENC
• CIK: 1211583
• Web: www.fennecpharma.com
• Phone: 919-636-4530
• Fax: 919-890-0490
• Employees: 10
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Adherex Technologies: $13.00
• High Price Target: $13.00
• Low Price Target: $13.00
• Potential Upside/Downside: +43.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$440 thousand
• Net Margins: -45.52%
• Pretax Margin: -45.53%
• Return on Equity: N/A
• Return on Assets: -26.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.13
• Quick Ratio: 4.97

Sales & Book Value

• Annual Sales: $47.54 million
• Price / Sales: 5.25
• Cash Flow: $0.03 per share
• Price / Cash Flow: 275.27
• Book Value: ($0.21) per share
• Price / Book: -43.05

Miscellaneous

• Outstanding Shares: 27,600,000
• Free Float: 24,354,000
• Market Cap: $249.50 million
• Optionable: Optionable
• Beta: 0.39